Aflibercept
- Generic Name
- Aflibercept
- Brand Names
- Eylea, Zaltrap, Yesafili
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 862111-32-8
- Unique Ingredient Identifier
- 15C2VL427D
- Background
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15%...
- Indication
The opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).
...
- Associated Conditions
- Branch Retinal Vein Occlusion With Macular Edema, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Macular Edema With Central Retinal Vein Occlusions, Metastatic Colorectal Cancer (CRC), Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD), Retinopathy of Prematurity (ROP)
- Associated Therapies
- -
Treat and Extend Analysis Trial With Aflibercept in Wet-AMD
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Michel Giunta
- Target Recruit Count
- 40
- Registration Number
- NCT04113538
- Locations
- 🇨🇦
GOGIUNTA, Sherbrooke, Quebec, Canada
Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity
- Conditions
- Interventions
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 127
- Registration Number
- NCT04101721
- Locations
- 🇻🇳
Regeneron Study Site, Hue, Vietnam
Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Minia University
- Target Recruit Count
- 400
- Registration Number
- NCT04087746
- Locations
- 🇪🇬
Minia University, Minya, Egypt
Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04079231
To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 263
- Registration Number
- NCT04058067
- Locations
- 🇨🇳
Novartis Investigative Site, Shanghai, China
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
- Conditions
- Interventions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Kodiak Sciences Inc
- Target Recruit Count
- 559
- Registration Number
- NCT04049266
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cole Eye Institute, Cleveland, Ohio, United States
🇺🇸Medical Center Ophthalmology Associates, San Antonio, Texas, United States
🇺🇸Vitreoretinal Surgery PA, Edina, Minnesota, United States
Aflibercept Plus Micropulse Laser Versus Aflibercept Monotherapy for Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- University of Alexandria
- Target Recruit Count
- 40
- Registration Number
- NCT04014556
A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
- Conditions
- Interventions
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Graybug Vision
- Target Recruit Count
- 56
- Registration Number
- NCT03953079
- Locations
- 🇺🇸
Cumberland Valley Retina Consultants, Hagerstown, Maryland, United States
🇺🇸California Retina Research Consultants, Bakersfield, California, United States
🇺🇸Southeast Retina Center, Augusta, Georgia, United States
Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 517
- Registration Number
- NCT03917472
- Locations
- 🇸🇰
Novartis Investigative Site, Zvolen, Slovakia
Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification
- Conditions
- Interventions
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Bay Area Retina Associates
- Target Recruit Count
- 32
- Registration Number
- NCT03832179
- Locations
- 🇺🇸
Bay Area Retina Associates, Walnut Creek, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.